Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: The EMPIRE Study

Current Medical Research and Opinion

Volumn 21, Issue 12, 2005, Pages 2029-2035

  Weissman, P ^a   Goldstein, B J ^b   Rosenstock, J ^c   Waterhouse, B ^d   Cobitz, A R ^d   Wooddell, Margaret J ^d   Strow, L J ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

EMPIRE; Glycemic control; Metformin; Rosiglitazone; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; ROSIGLITAZONE;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AGED; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MEDICAL SOCIETY; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL TRACT; HUMANS; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 29144496022     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X74844     Document Type: Conference Paper

References (24)

1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27(Suppl 1):S15-S34
2. American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management - 2002 update. Endocr Pract 2002;8(Suppl 1):40-82
3. European Diabetes Policy Group. A desktop guide to type 2 diabetes. Diabet Med 1999;16:716-30
4. Campbell IW. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol 2000;7:625-31
5. Garber AJ. Using dose-response characteristics of therapeutic agents for treatment decisions in type 2 diabetes. Diabetes Obes Metab 2000;2:139-47
6. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) [UK Prospective Diabetes Study (UKPDS) Group]. J Am Med Assoc 1999;281:2005-12
7. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33
8. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. New Engl J Med 1998;338:867-72
9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
10. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001;44:2210-19
11. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51:797-802
12. Hallsten K, Virtanen KA, Lonnqvist F, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002;51:3479-85
13. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004;21:568-76
14. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8
15. Smith SA, Porter LE, Biswas N, et al. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. J Clin Endocrinol Metab 2004;89:6048-53
16. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. J Am Med Assoc 2000;283:1695-702
17. Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-34
18. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003;5:163-70
19. Carey DG, Cowin GJ, Galloway GJ, et al. Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients. Obes Res 2002;10:1008-15
20. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-8
21. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101:975-80
22. Home P, Pocock S, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): an interim analysis of glycaemia at 18 months. Diabetologia 2004;47(Suppl 1):A262
23. Home P, Komajada M, Beck-Nielsen H, et al. Twelve months sustained efficacy of rosiglitazone combination therapy on ambulatory blood pressure (ABP) in people with type 2 diabetes mellitus. Diabetes 2005;54(Suppl 2):[Abstract 542-P]
24. Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25:1737-43